Latham Advises the Underwriters in Adagene’s US IPO

Cross-border capital markets team supports a Chinese leading biopharmaceutical company in raising US$140 million in Nasdaq initial public offering.

February 24, 2021

Latham & Watkins advised the underwriters in Adagene Inc.’s initial public offering of 7,354,000 American Depositary Shares on the Nasdaq under the symbol ADAG for a total offering size of approximately US$140 million. Goldman Sachs, Morgan Stanley and Jefferies acted as the joint bookrunners on the offering.

Adagene is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. The company combines computational biology and artificial intelligence to design novel antibodies that address unmet patient needs.

The Latham team was led by Hong Kong partners Cathy Yeung, Benjamin Su, Daying Zhang, and San Diego partner Michael Sullivan, with associates Chimmy Tao and Jeffrey Woodley. Advice on tax matters was provided by partner Samuel Weiner in Los Angeles and associate Janet Hsu in Orange County; on FDA regulatory matters by partner Elizabeth Richards and associate Barrett Tenbarge in Washington D.C.; on IP matters by partner Chris Hazuka and associate Robert Yeh in San Diego.

Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.